Arecor Therapeutics plc AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES AT278 demonstrates.
Today, Boehringer Ingelheim and CBmed GmbH Center for Biomarker Research in Medicine (CBmed) announced a long-term strategic partnership. Jointly the partners will apply translational medicine approaches to accelerate the development of first-in-class medicines to transform the lives of people with cancer and .
Hypoglycemia rates didn t differ between weekly insulin icodec and daily glargine even when intentionally doubling and tripling the doses, although those parts of the study each lasted just 1 day.